More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds.
The use of tyrosine kinase inhibitors (TKIs) in the treatment of solid tumors is the expected standard of care for many types of tumors. Since the description of signal transduction pathways, followed by the development of small molecules designed to inhibit those pathways, there has been significant improvement not only in progression-free survival and overall survival but also in aiming toward chemotherapy-free treatment of solid tumors to maximize quality of life. This article reviews available TKIs and discusses toxicity, dosing, and resistance.
Department of Haematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charitè Medical University, Berlin, Germany.
Maria
M
Vergoulidou
EGFR mutation; TKI toxicities; TKIs; signaling pathways; solid tumors; targeted therapy; tyrosine kinase inhibitors